A habitat for intelligence woven directly into sight itself
En un laboratorio de Dubái, una empresa fundada por físicos está intentando lo que los gigantes tecnológicos no han logrado: disolver la frontera entre la percepción humana y la inteligencia digital, no a través de gafas o pantallas, sino directamente sobre el ojo. Xpanceo, con respaldo de 250 millones de dólares y más de cien científicos, apuesta a que el próximo salto en la interfaz humano-máquina no se llevará en la cara, sino en la córnea. Es una promesa que mezcla nanofísica, medicina y ambición civilizatoria, pero que aún debe superar los mismos muros que sepultaron a quienes intentaron algo parecido antes.
- Xpanceo está construyendo lentes de contacto con materiales de escala atómica que integran IA, sensores de salud y realidad aumentada directamente sobre el ojo, eliminando las limitaciones ópticas de las gafas AR convencionales.
- La empresa recaudó 250 millones de dólares en julio de 2025 —la mayor inversión registrada en el sector de AR, VR y wearables— y rechazó ofertas de adquisición de grandes firmas tecnológicas y farmacéuticas.
- La validación clínica avanza: una prueba con implante intracorneal en colaboración con la empresa italiana Intra-Ker demostró que la plataforma óptica puede proyectar imágenes directamente sobre la retina.
- El primer prototipo completamente integrado está previsto para finales de 2026, pero la certificación regulatoria, la fabricación a escala y la biocompatibilidad a largo plazo siguen siendo obstáculos sin resolver.
- El precedente de Mojo Vision —que gastó más de cien millones de dólares y abandonó un proyecto similar— recuerda que el dinero y la ciencia no garantizan que una tecnología llegue al mundo.
En un laboratorio de Dubái, un equipo de físicos e ingenieros está construyendo lentes de contacto fabricadas con materiales de escala atómica, capaces de medir glucosa en sangre, monitorear la presión intraocular y proyectar información directamente sobre la visión del usuario. Xpanceo, fundada en 2021 por Roman Axelrod y el nanofísico Valentyn Volkov, no busca crear otra pantalla: describe su trabajo como la construcción de un «hábitat para la inteligencia», una capa computacional tejida dentro de la propia mirada.
Lo que distingue este enfoque de las gafas de realidad aumentada es la proximidad. Al posarse directamente sobre el ojo, la lente elimina el deslumbramiento, los ángulos muertos y las ineficiencias ópticas que afectan a los cascos AR. Un dispositivo externo gestiona el procesamiento pesado y transmite energía de forma inalámbrica a la lente, que actúa simultáneamente como sensor biológico e interfaz visual. En cuatro años, el equipo ha desarrollado más de veinticinco prototipos y registrado dieciocho solicitudes de patente que cubren cincuenta y siete invenciones distintas.
En julio de 2025, la empresa cerró una ronda de 250 millones de dólares que la valoró en 1.350 millones —la mayor inversión jamás registrada en el sector— y rechazó al menos dos ofertas de adquisición de grandes compañías tecnológicas y farmacéuticas. La estrategia de salida al mercado pasa primero por la medicina: una prueba con implante intracorneal en colaboración con la italiana Intra-Ker demostró que la plataforma puede restaurar visión en un ojo donante, validando que la tecnología funciona más allá del papel.
Sin embargo, el camino está sembrado de advertencias. Mojo Vision, otra startup con ambiciones similares, invirtió más de cien millones de dólares antes de abandonar el proyecto. La fabricación sin defectos a escala industrial, la aprobación regulatoria y la biocompatibilidad sostenida en el tiempo son problemas que el dinero no resuelve solo. Xpanceo prevé presentar su primer prototipo integrado a finales de 2026, con una demostración pública en 2027. Si logra cruzar esos umbrales, podría redefinir la relación entre el cuerpo humano y la inteligencia digital. Si no, se sumará a la larga lista de visiones que se detuvieron justo antes de volverse reales.
In a Dubai laboratory, a team of physicists and engineers is working on something that sounds like science fiction but is already taking shape in the real world: contact lenses so thin they're built from atomic-scale materials, embedded with artificial intelligence, health sensors, and the ability to display information directly onto the eye. Xpanceo, founded in 2021 by Roman Axelrod and physicist Valentyn Volkov, is pursuing what the major tech companies—Apple, Meta, Google, Samsung—have been chasing through bulky glasses: a seamless bridge between human perception and digital intelligence. But Xpanceo's bet is that the future doesn't live on your face. It lives on your eye.
The company's vision is not to create another screen. Instead, Xpanceo describes its work as building a "habitat for intelligence," a layer of computational awareness woven directly into sight itself. Volkov, one of the most cited researchers in nanophotonics, provides the scientific foundation. Over four years, the team has produced more than twenty-five working prototypes, each one pushing past the same stubborn problems: how to pack enough power into something thinner than a human hair, how to make it flexible enough to wear comfortably, how to keep it safe. The latest versions include tiny interactive displays, biosensors that measure blood glucose and the pressure inside the eye, and miniaturized solid-state batteries. A separate device worn on the body handles the heavy computational lifting and beams power wirelessly to the lens.
What makes this different from existing augmented reality glasses is proximity. Because the lens sits directly against the eye, it eliminates the optical compromises that plague AR headsets: no glare washing out the display, no dead zones in your peripheral vision, almost perfect optical efficiency. The closeness to the retina means the system can run on far less power while delivering sharper images. The lens becomes both a sensor and an interface—it watches your eye and the world around it, collects biological data in real time, sends that information to cloud-based AI models, and returns insights through your vision. For pilots, astronauts, elite athletes, and patients needing constant medical monitoring, the applications are obvious. The lens can see what you see and know what your body is doing simultaneously.
Xpanceo has assembled a hundred scientists and engineers in Dubai, half of them holding doctorates. The company holds eighteen patent applications covering fifty-seven distinct inventions. In July 2025, it raised two hundred fifty million dollars in funding that valued the company at one point three five billion dollars—the largest investment ever recorded in the augmented reality, virtual reality, and wearables sector. The company turned down at least two acquisition offers from major technology and pharmaceutical firms. Nature Index ranked Xpanceo among the world's top three physics companies.
The path to market runs through medicine first. Xpanceo has partnered with Intra-Ker, an Italian company, to test an intracorneal implant that projects images directly onto the retina of a donor eye—a proof of concept that the optical platform actually works and that it can restore sight. That validation matters. It means the underlying technology is not theoretical. Medical and industrial applications will come before consumer products, where regulatory hurdles are lower and manufacturing scale is more manageable. The company plans to unveil its first fully integrated smart contact lens prototype by the end of 2026, with a public demonstration expected in early 2027.
But history offers a cautionary note. Mojo Vision, another startup pursuing smart contact lenses, spent more than a hundred million dollars and ultimately abandoned the project. The obstacles are real: manufacturing at scale without defects, obtaining regulatory approval from health authorities, ensuring the lenses remain biocompatible over years of continuous wear. These are not engineering problems that money alone solves. They are problems that require time, iteration, and luck. Axelrod has described the work as steps toward a continuous interaction with an omnipresent intelligent layer, one that could assist in managing every aspect of human life and grant capabilities previously unimaginable. Whether that vision becomes reality depends on whether Xpanceo can clear the hurdles that have stopped others before them.
Citas Notables
A habitat for intelligence where barriers between the user and digital tools disappear— Roman Axelrod, Xpanceo founder, to Forbes
Steps toward continuous interaction with an omnipresent intelligent layer capable of assisting in managing all aspects of human life— Roman Axelrod, describing the company's long-term vision
La Conversación del Hearth Otra perspectiva de la historia
Why contact lenses instead of glasses? Glasses seem easier to manufacture and regulate.
Glasses sit six millimeters from your eye. A contact lens sits directly on the cornea. That proximity changes everything—you get better optics, lower power consumption, and the lens can measure things happening inside the eye itself, like intraocular pressure. You can't do that from a distance.
So the real advantage is medical sensing, not the AR display?
Both matter, but yes—the sensing is what makes this different. You're not just showing information; you're collecting biological data continuously. That's the "habitat for intelligence" they talk about.
They've built twenty-five prototypes in four years. Why is it taking so long?
Because every component has to be impossibly small and impossibly reliable. A battery the size of a grain of sand that won't leak chemicals into your eye. A display that doesn't cause inflammation. Materials that flex without cracking. One failure and the whole thing fails.
Mojo Vision spent over a hundred million and quit. What makes Xpanceo different?
They've already validated the core technology with the intracorneal implant trials. They know the optics work. They have more patents, more funding, and they're being more strategic about where they launch first—medical and industrial, not consumer.
When will regular people actually be able to buy these?
Honestly, probably not for several years. They're targeting late 2026 for a prototype, but that's not a product. Regulatory approval, manufacturing scale, long-term safety data—those are the real timelines. Maybe 2028 or 2029 for early medical applications. Consumer? That's a guess.